Sanofi Introduces Breakthrough Tolebrutinib for Non-relapsing Secondary Progressive Multiple Sclerosis
Sanofi has introduced tolebrutinib, an investigational treatment for adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Tolebrutinib is a novel oral Bruton’s tyrosine kinase (BTK) inhibitor that is brain-penetrant and bioactive. It achieves cerebrospinal fluid concentrations capable of modulating B lymphocytes and disease-associated microglia, key drivers of multiple sclerosis (MS) progression.
Currently undergoing phase 3 clinical trials, tolebrutinib is being evaluated for the treatment of various forms of MS. Its safety and efficacy have not yet been assessed by any regulatory authority globally.
Multiple sclerosis is a chronic, immune-mediated neurodegenerative condition that can lead to the accumulation of irreversible physical and cognitive disabilities over time. This progressive decline significantly impacts patients' overall health and quality of life. Addressing disability accumulation remains a critical unmet need in MS treatment.
Existing therapies for MS primarily target peripheral B and T cells, focusing on the adaptive immune system. However, these approaches often neglect innate immunity, which is believed to contribute to disability progression.
Additionally, many approved or experimental treatments do not act directly within the central nervous system to deliver clinical benefits.
Tolebrutinib stands out as the first and only brain-penetrant BTK inhibitor for MS to receive breakthrough therapy designation from the FDA.
